Noninvasive preimplantation genetic testing for aneuploidy exhibits high rates of deoxyribonucleic acid amplification failure and poor correlation with results obtained using trophectoderm biopsy

Fertil Steril. 2021 Jun;115(6):1461-1470. doi: 10.1016/j.fertnstert.2021.01.028. Epub 2021 Mar 19.

Abstract

Objective: To validate a commercially available noninvasive preimplantation genetic testing for aneuploidy (niPGT-A) assay by investigating the following: prevalence of deoxyribonucleic acid (DNA) amplification failure with niPGT-A; factors affecting amplification failure with niPGT-A; and frequency of discordant results between niPGT-A and traditional preimplantation genetic testing for aneuploidy.

Design: Prospective cohort study SETTING: Academic-affiliated private practice PATIENT(S): One hundred sixty-six blastocysts and their surrounding culture media from couples undergoing in vitro fertilization between July 2019 and May 2020 were analyzed.

Intervention(s): Blastocyst-stage spent culture media samples underwent niPGT-A using a commercially available kit that used whole-genome amplification with a modified multiple annealing and looping-based amplification cycle protocol followed by next-generation sequencing. Preimplantation genetic testing for aneuploidy of trophectoderm (TE) biopsies was performed using targeted next-generation sequencing.

Main outcome measure(s): The primary outcome was failure to achieve an interpretable result with niPGT-A. Factors affecting DNA amplification were also assessed. Discrepancies between niPGT-A and TE biopsy results were analyzed, and clinical outcomes were evaluated.

Result(s): Deoxyribonucleic acid amplification failures with niPGT-A were observed in 37.3% (62/166) of the samples. With TE biopsy, no embryos exhibited DNA amplification failure. Embryos with a shorter duration of exposure to the culture media and no evidence of whole-chromosome aneuploidy on the TE biopsy displayed high rates of DNA amplification failure with niPGT-A. Of 104 embryos with both niPGT-A and TE biopsy results available, whole-chromosome discordance was noted in 42 cases (40.4%). Three embryos classified as aneuploid based on the niPGT-A result progressed to successful delivery.

Conclusion(s): The rates of DNA amplification failure were high among the niPGT-A samples, virtually precluding the clinical applicability of niPGT-A in its current form.

Keywords: Embryo culture; ICSI; IVF; noninvasive PGT-A; preimplantation genetic testing.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aneuploidy*
  • Blastocyst / metabolism
  • Blastocyst / pathology*
  • Culture Media / metabolism
  • Embryo Culture Techniques
  • Embryo Implantation
  • Embryo Transfer
  • Female
  • Fertility
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Infertility / diagnosis
  • Infertility / physiopathology
  • Infertility / therapy*
  • Live Birth
  • Male
  • Noninvasive Prenatal Testing*
  • Nucleic Acid Amplification Techniques*
  • Predictive Value of Tests
  • Pregnancy
  • Pregnancy Rate
  • Preimplantation Diagnosis*
  • Reproducibility of Results
  • Sperm Injections, Intracytoplasmic* / adverse effects
  • Time Factors
  • Treatment Outcome
  • Whole Genome Sequencing*

Substances

  • Culture Media